Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
Elisa Vergari, Jakob G Knudsen, Reshma Ramracheya, Albert Salehi, Quan Zhang, Julie Adam, Ingrid Wernstedt Asterholm, Anna Benrick, Linford J B Briant, Margarita V Chibalina, Fiona M Gribble, Alexander Hamilton, Benoit Hastoy, Frank Reimann, Nils J G Rorsman, Ioannis I Spiliotis, Andrei Tarasov, Yanling Wu, Frances M Ashcroft, Patrik Rorsman, Elisa Vergari, Jakob G Knudsen, Reshma Ramracheya, Albert Salehi, Quan Zhang, Julie Adam, Ingrid Wernstedt Asterholm, Anna Benrick, Linford J B Briant, Margarita V Chibalina, Fiona M Gribble, Alexander Hamilton, Benoit Hastoy, Frank Reimann, Nils J G Rorsman, Ioannis I Spiliotis, Andrei Tarasov, Yanling Wu, Frances M Ashcroft, Patrik Rorsman
Abstract
Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin's capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin's hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes. 2014;63:2188–2195. doi: 10.2337/db14-0059.
- Unger RH. Letter: glucagon in pathogenesis of diabetes. Lancet. 1975;1:1036–1032. doi: 10.1016/S0140-6736(75)91985-6.
- Cryer PE. Managing diabetes: lessons from Type 1 diabetes mellitus. Diabet. Med. 1998;15(Suppl 4):S8–S12. doi: 10.1002/(SICI)1096-9136(1998120)15:4+<S8::AID-DIA742>;2-P.
- Frier BM. The incidence and impact of hypoglycemia in type 1 and type 2 diabetes. Int. Diabetes Monit. 2009;21:210–218.
- Skrivarhaug T, et al. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia. 2006;49:298–305. doi: 10.1007/s00125-005-0082-6.
- Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45:937–948. doi: 10.1007/s00125-002-0822-9.
- Cabrera O, et al. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. USA. 2006;103:2334–2339. doi: 10.1073/pnas.0510790103.
- Rorsman P, Huising MO. The somatostatin-secreting pancreatic delta-cell in health and disease. Nat. Rev. Endocrinol. 2018;14:404–414. doi: 10.1038/s41574-018-0020-6.
- Zhang Q, et al. R-type Ca(2+)-channel-evoked CICR regulates glucose-induced somatostatin secretion. Nat. Cell Biol. 2007;9:453–460. doi: 10.1038/ncb1563.
- Pipeleers DG, Schuit FC, Van Schravendijk CF, Van de Winkel M. Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology. 1985;117:817–823. doi: 10.1210/endo-117-3-817.
- Pipeleers DG, et al. Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology. 1985;117:824–833. doi: 10.1210/endo-117-3-824.
- Hauge-Evans AC, et al. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes. 2009;58:403–411. doi: 10.2337/db08-0792.
- Vieira E, Salehi A, Gylfe E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia. 2007;50:370–379. doi: 10.1007/s00125-006-0511-1.
- Macdonald PE, et al. A KATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol. 2007;5:e143. doi: 10.1371/journal.pbio.0050143.
- Yue JT, et al. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes. 2012;61:197–207. doi: 10.2337/db11-0690.
- Karimian N, et al. Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats. Diabetes. 2013;62:2968–2977. doi: 10.2337/db13-0164.
- Gopel SO, Kanno T, Barg S, Rorsman P. Patch-clamp characterisation of somatostatin-secreting -cells in intact mouse pancreatic islets. J. Physiol. 2000;528:497–507. doi: 10.1111/j.1469-7793.2000.00497.x.
- Gable KL, et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol. Cancer Ther. 2006;5:1079–1086. doi: 10.1158/1535-7163.MCT-05-0397.
- Heding LG. Specific and direct radioimmunoassay for human proinsulin in serum. Diabetologia. 1977;13:467–474. doi: 10.1007/BF01234498.
- Blodgett TJ, Gardner SE, Blodgett NP, Peterson LV, Pietraszak M. A tool to assess the signs and symptoms of catheter-associated urinary tract infection: development and reliability. Clin. Nurs. Res. 2015;24:341–356. doi: 10.1177/1054773814550506.
- Kailey B, et al. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. Am. J. Physiol. Endocrinol. Metab. 2012;303:E1107–E1116. doi: 10.1152/ajpendo.00207.2012.
- Adriaenssens AE, et al. Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia. 2016;59:2156–2165. doi: 10.1007/s00125-016-4033-1.
- Davis SN, Shavers C, Costa F. Differential gender responses to hypoglycemia are due to alterations in CNS drive and not glycemic thresholds. Am. J. Physiol. Endocrinol. Metab. 2000;279:E1054–E1063. doi: 10.1152/ajpendo.2000.279.5.E1054.
- Davis SN, Shavers C, Costa F. Gender-related differences in counterregulatory responses to antecedent hypoglycemia in normal humans. J. Clin. Endocrinol. Metab. 2000;85:2148–2157.
- Merovci A, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 2014;124:509–514. doi: 10.1172/JCI70704.
- Ferrannini E, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 2014;124:499–508. doi: 10.1172/JCI72227.
- Bonner C, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 2015;21:512–517. doi: 10.1038/nm.3828.
- Pedersen MG, Ahlstedt I, El Hachmane MF, Gopel SO. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci. Rep. 2016;6:31214. doi: 10.1038/srep31214.
- Millar P, et al. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J. Endocrinol. 2017;234:255–267. doi: 10.1530/JOE-17-0263.
- Ghezzi C, Wright EM. Regulation of the human Na+ -dependent glucose cotransporter hSGLT2. Am. J. Physiol. Cell. Physiol. 2012;303:C348–C354. doi: 10.1152/ajpcell.00115.2012.
- Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol. Rev. 2011;91:733–794. doi: 10.1152/physrev.00055.2009.
- Adam J, et al. Fumarate hydratase deletion in pancreatic beta cells leads to progressive diabetes. Cell Rep. 2017;20:3135–3148. doi: 10.1016/j.celrep.2017.08.093.
- Wang MY, et al. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes. Proc. Natl. Acad. Sci. USA. 2017;114:6611–6616. doi: 10.1073/pnas.1705845114.
- Kawamori D, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell. Metab. 2009;9:350–361. doi: 10.1016/j.cmet.2009.02.007.
- Samols E, Stagner JI, Ewart RB, Marks V. The order of islet microvascular cellular perfusion is B----A----D in the perfused rat pancreas. J. Clin. Invest. 1988;82:350–353. doi: 10.1172/JCI113593.
- Stagner JI, Samols E, Bonner-Weir S. Beta----alpha----delta pancreatic islet cellular perfusion in dogs. Diabetes. 1988;37:1715–1721. doi: 10.2337/diab.37.12.1715.
- Braun M, et al. Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia. 2009;52:1566–1578. doi: 10.1007/s00125-009-1382-z.
- Rorsman P, Ashcroft FM. Pancreatic beta-cell electrical activity and insulin secretion: of mice and men. Physiol. Rev. 2018;98:117–214. doi: 10.1152/physrev.00008.2017.
- Chera S, et al. Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature. 2014;514:503–507. doi: 10.1038/nature13633.
- Adriaenssens A, et al. A transcriptome-led exploration of molecular mechanisms regulating somatostatin-producing D-cells in the gastric epithelium. Endocrinology. 2015;156:3924–3936. doi: 10.1210/en.2015-1301.
- Kulkarni RN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96:329–339. doi: 10.1016/S0092-8674(00)80546-2.
- Zhang Q, et al. Na + current properties in islet alpha- and beta-cells reflect cell-specific Scn3a and Scn9a expression. J. Physiol. 2014;592:4677–4696. doi: 10.1113/jphysiol.2014.274209.
- Ramracheya R, et al. Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes. 2010;59:2198–2208. doi: 10.2337/db09-1505.
- Braun M, et al. Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes. 2008;57:1618–1628. doi: 10.2337/db07-0991.
- Zhang Q, et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes. Cell. Metab. 2013;18:871–882. doi: 10.1016/j.cmet.2013.10.014.
Source: PubMed